These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27704173)

  • 1. The biophysics, biochemistry and physiology of CFTR.
    Moran O
    Cell Mol Life Sci; 2017 Jan; 74(1):1-2. PubMed ID: 27704173
    [No Abstract]   [Full Text] [Related]  

  • 2. Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis.
    Yeh JT; Yu YC; Hwang TC
    J Physiol; 2019 Jan; 597(2):543-560. PubMed ID: 30408177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The G551D CFTR chloride channel spurs the development of personalized medicine.
    Fischer H
    J Physiol; 2014 May; 592(9):1907-8. PubMed ID: 24786148
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of cystic fibrosis transmembrane conductance regulator phenylalanine 508 side chain in ion channel gating.
    Cui L; Aleksandrov L; Hou YX; Gentzsch M; Chen JH; Riordan JR; Aleksandrov AA
    J Physiol; 2006 Apr; 572(Pt 2):347-58. PubMed ID: 16484308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The gating of the CFTR channel.
    Moran O
    Cell Mol Life Sci; 2017 Jan; 74(1):85-92. PubMed ID: 27696113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating.
    Yang H; Shelat AA; Guy RK; Gopinath VS; Ma T; Du K; Lukacs GL; Taddei A; Folli C; Pedemonte N; Galietta LJ; Verkman AS
    J Biol Chem; 2003 Sep; 278(37):35079-85. PubMed ID: 12832418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. G551D and G1349D, two CF-associated mutations in the signature sequences of CFTR, exhibit distinct gating defects.
    Bompadre SG; Sohma Y; Li M; Hwang TC
    J Gen Physiol; 2007 Apr; 129(4):285-98. PubMed ID: 17353351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revertant mutants modify, but do not rescue, the gating defect of the cystic fibrosis mutant G551D-CFTR.
    Xu Z; Pissarra LS; Farinha CM; Liu J; Cai Z; Thibodeau PH; Amaral MD; Sheppard DN
    J Physiol; 2014 May; 592(9):1931-47. PubMed ID: 24591578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploiting species differences to understand the CFTR Cl- channel.
    Bose SJ; Scott-Ward TS; Cai Z; Sheppard DN
    Biochem Soc Trans; 2015 Oct; 43(5):975-82. PubMed ID: 26517912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of disease-associated cystic fibrosis transmembrane conductance regulator mutants by hydrolyzable ATP analogs.
    Miki H; Zhou Z; Li M; Hwang TC; Bompadre SG
    J Biol Chem; 2010 Jun; 285(26):19967-75. PubMed ID: 20406820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro CFTR folding assays.
    Stidham RD; Wigley WC; Thomas PJ
    Methods Mol Med; 2002; 70():311-22. PubMed ID: 11917534
    [No Abstract]   [Full Text] [Related]  

  • 12. On the mechanism of gating defects caused by the R117H mutation in cystic fibrosis transmembrane conductance regulator.
    Yu YC; Sohma Y; Hwang TC
    J Physiol; 2016 Jun; 594(12):3227-44. PubMed ID: 26846474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease-associated mutations in the fourth cytoplasmic loop of cystic fibrosis transmembrane conductance regulator compromise biosynthetic processing and chloride channel activity.
    Seibert FS; Linsdell P; Loo TW; Hanrahan JW; Clarke DM; Riordan JR
    J Biol Chem; 1996 Jun; 271(25):15139-45. PubMed ID: 8662892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [From the laboratory to the clinic: CFTR and the therapeutic options for cystic fibrosis].
    Mayol J; Alvarez de Arcaya Vicente A; Arbeo Escolar AM; Peña Soria MJ; Alvarez Fernández-Represa J
    An Med Interna; 2000 Feb; 17(2):92-8. PubMed ID: 10829466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucin secretion mediated by the cystic fibrosis gene protein, CFTR.
    Pereira MM; Dormer RL; McPherson MA
    Biochem Soc Trans; 1995 Nov; 23(4):532S. PubMed ID: 8654717
    [No Abstract]   [Full Text] [Related]  

  • 16. Introduction to section III: biochemical methods to study CFTR protein.
    Amaral MD; Lukacs GL
    Methods Mol Biol; 2011; 741():213-8. PubMed ID: 21594787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocytic trafficking of CFTR in health and disease.
    Ameen N; Silvis M; Bradbury NA
    J Cyst Fibros; 2007 Jan; 6(1):1-14. PubMed ID: 17098482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [CFTR and transepithelial ionic transport abnormalities in cystic fibrosis].
    Becq F
    Arch Pediatr; 2003 Sep; 10 Suppl 2():325s-332s. PubMed ID: 14671929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defects in processing and trafficking of cystic fibrosis transmembrane conductance regulator.
    Kunzelmann K; Nitschke R
    Exp Nephrol; 2000; 8(6):332-42. PubMed ID: 11014930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What we know and what we do not know about cystic fibrosis transmembrane conductance regulator.
    Ma J; Davis PB
    Clin Chest Med; 1998 Sep; 19(3):459-71, v-vi. PubMed ID: 9759549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.